New imaging technique may forecast lymphoma treatment response
NCT ID NCT07657494
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study explores whether advanced PET/CT scans using special tracers can predict how well patients with aggressive lymphoma will respond to treatment and their long-term outlook. Researchers will inject two types of imaging agents—FAPI and Grazytracer—to visualize the tumor's environment, including cancer-associated fibroblasts and immune cell activity. The goal is to develop models that help doctors identify patients at risk of relapse or resistance early on.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Al18F-NOTA-FAPI and Al18F-NOTA-grazytracer/68Ga-grazytracer (imaging tracers)
What this could lead to
If successful, these imaging methods could help doctors predict which patients will respond to treatment and who might relapse, enabling more personalized care.
What could go wrong
This is an early-stage observational study with only 94 participants, so results may not apply broadly. The imaging tracers are experimental and not yet proven to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGGRESSIVE LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITINGBeijing, Chao Yang, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••